INTO: new projects and research

INTO is the strategic alliance formed in 2022, bringing together Sterling, DFE Pharma, and Harro to develop innovative solutions in inhalation technology. Over the years, this collaboration has grown stronger, reinforcing our commitment to improving therapies for respiratory diseases and driving innovation in this ever-evolving field. In 2024, INTO expanded its scientific efforts through significant studies, contributing to numerous publications on the international stage. These contributions were presented at high-profile scientific conferences, such as RDD Asia and DDL Edinburgh, further cementing our leadership in the inhalation domain. The most notable examples of this work became publications presented in Kerala, India, and Edinburgh, UK, respectively titled:

• "Relvar® Ellipta Generic: Development of Vilanterol and Fluticasone Furoate In Vitro Bioequivalent Formulations"
• "Approaches to Optimizing Dry Powder Inhaler Formulation"

Thanks to this collaboration, we are now able to offer integrated services across the entire development process for inhalation drugs. Our solutions span formulation and device design, clinical studies, and production.

INTO is the strategic alliance formed in 2022, bringing together Sterling, DFE Pharma, and Harro to develop innovative solutions in inhalation technology. Over the years, this collaboration has grown stronger, reinforcing our commitment to improving therapies for respiratory diseases and driving innovation in this ever-evolving field. In 2024, INTO expanded its scientific efforts through significant studies, contributing to numerous publications on the international stage. These contributions were presented at high-profile scientific conferences, such as RDD Asia and DDL Edinburgh, further cementing our leadership in the inhalation domain. The most notable examples of this work became publications presented in Kerala, India, and Edinburgh, UK, respectively titled:

• "Relvar® Ellipta Generic: Development of Vilanterol and Fluticasone Furoate In Vitro Bioequivalent Formulations"
• "Approaches to Optimizing Dry Powder Inhaler Formulation"

Thanks to this collaboration, we are now able to offer integrated services across the entire development process for inhalation drugs. Our solutions span formulation and device design, clinical studies, and production.